By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

MedImmune 

One MedImmune Way

Gaithersburg  Maryland  20878  U.S.A.
Phone: 301-398-0000 Fax: 301-398-9000


SEARCH JOBS

MedImmune is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom, and the Netherlands. UK facilities include vaccine manufacturing operations in Speke and antibody discovery and research laboratories in Cambridge.

With two marketed products and an advancing pipeline of promising candidates in the areas of infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience, MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees.

Key Statistics


Email:
Ownership: Public

Web Site: MedImmune
Employees: 3,000
Symbol: AZN
 



Industry
Biotechnology






Company News
Advaxis, Inc. Announces FDA Acceptance Of Its Investigational New Drug Application To Commence Clinical Trials Of ADXS-HPV In Combination With MedImmune (AZN)'s MEDI4736 For The Treatment Of HPV-Associated Cancers 12/15/2014 7:24:48 AM
Immunocore And MedImmune (AZN) Win The SCRIP Award For Best Partnership Alliance 2014 12/10/2014 9:01:20 AM
MedImmune (AZN) Presents Positive Phase 2b Data For Mavrilimumab In Rheumatoid Arthritis At American College of Rheumatology Annual Meeting 11/17/2014 11:40:06 AM
MedImmune (AZN) Presents Promising New Data In Systemic Lupus At American College of Rheumatology Meeting 11/17/2014 11:34:23 AM
MDBio Foundation Receives $50,000 Grant From AstraZeneca PLC (AZN) And MedImmune (AZN) 11/10/2014 10:45:22 AM
Inovio Pharmaceuticals (INO), MedImmune (AZN) And University of Pennsylvania Partner To Combat Influenza And Antibiotic Resistant Bacteria 10/21/2014 10:42:42 AM
Inovio Pharmaceuticals (INO), MedImmune (AZN) And The University of Pennsylvania Partner To Combat Influenza And Antibiotic Resistant Bacteria 10/21/2014 8:04:18 AM
AgonOx’s OX40 Platform Being Utilized In MedImmune (AZN)’s Phase 1 OX40 Agonist Study 10/20/2014 9:22:39 AM
MedImmune (AZN) Receives Fast Track Designation From FDA For Development Of MEDI3902 For Prevention Of Nosocomial Pneumonia 9/23/2014 10:42:42 AM
Allozyne, Inc. Sold For Scrap As MedImmune (AZN) Snaps Up Rights 9/19/2014 6:50:12 AM
12345678910...
//-->